NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
September 26, 2006 • Volume 3 / Number 37 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Tanning Study Suggests Strategies for Preventing Skin Cancer

Director's Update
Workshop Helps RAID Program Adapt, Evolve

Cancer Research Highlights
Common Prostate Cancer Treatment May Increase Diabetes Risk

Gemcitabine Plus Carboplatin Benefits Women with Recurrent Ovarian Cancer

Advanced Cancer Patients Benefit More from Aromatase Inhibitors than Tamoxifen

Rising Kidney Cancer Mortality Challenges Treatment Standards

Age Associated with Type of Breast Cancer Treatment

Spotlight
Answers, and More Questions, Emerging on Pediatric Leukemia

Featured Clinical Trial
Combining Targeted Therapies for Thoracic Cancers

Notes
NCI Director's Awards Ceremony Scheduled in October

Save the Date for AIDS Malignancy Program Conference

FARE 2007 Winners Are Awarded

SBIR Program Announces New Contract Funding Opportunities

Community Update
NCI Cooperative Groups Celebrate 50th Anniversary on Capitol Hill

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

Tanning Study Suggests Strategies for Preventing Skin Cancer

Researchers have identified a drug that bypasses a genetic predisposition and induces tanning in mice prone to sunburns and skin cancer. The result is "sunless" tanning that offers mice some protection against skin damage from ultraviolet (UV) light.

The drug, called forskolin, supplies a signal that's weak or missing in the skin cells of fair-skinned mice. Without this signal, the cells make red or blond pigment rather than brown or black.

By rubbing forskolin cream on fair-skinned mice once a day for several weeks, researchers at the Dana-Farber Cancer Institute caused the mice to produce dark pigment that was largely indistinguishable from that of brown or black mice.  Read more  



Director's Update

Guest Update by Dr. James Doroshow

Workshop Helps RAID Program Adapt, Evolve

Dr. James DoroshowLaunched in 1998, NCI's Rapid Access to Intervention Development (RAID) program has become an important resource for investigators engaged in anticancer therapeutics development. In July 2005, a workshop was held to comprehensively review the RAID program, and determine ways to improve its effectiveness and overall operation.

The report from that workshop - which was chaired by Dr. John Mendelsohn of the University of Texas M.D. Anderson Cancer Center, and involved experts in cancer research and drug development from the country's top academic centers and industry - includes important recommendations that should greatly strengthen NCI's drug development capabilities.  

As Dr. Niederhuber explained earlier this year in the NCI Cancer Bulletin, RAID provides a bridge between discovery and the introduction of an agent into phase 0 or phase I human clinical trials by offering invaluable support - including bulk drug production, formulation, pharmacokinetics, and toxicity testing, among others - to principal investigators (PIs) working on the development of small-molecule drugs and biologics.  Read more  


The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov